文献速递细胞病理与分子病理神经与头颈病理

配对微小RNA表达分析在甲状腺细针穿刺样本中识别甲状腺髓样癌的分析与临床验证

Analytical and clinical validation of pairwise microRNA expression analysis to identify medullary thyroid cancer in thyroid fine-needle aspiration samples.
PubMed 文献 · Cancer Cytopathol · 2020-10-05

研究提出对ThyraMIR检测中10种miRNA进行配对差值分析(diff-pair),以识别甲状腺细针穿刺样本中的甲状腺髓样癌(MTC)。发现队列30例(含4例MTC)中9个配对差异有显著区分力(P < .0001);分析验证及3个临床验证队列(共7557份标本)中检测均正确分类,总体准确率100%(95%CI 99%-100%);在细胞学不确定样本中,配对分析灵敏度高于MTC特异性突变分析(100% vs 25%;P = .03)。

要点

  • 配对miRNA表达分析可准确识别甲状腺FNA样本中的MTC。
  • 总体检测准确率100%(95%CI 99%-100%)。
  • 细胞学不确定样本中配对分析灵敏度优于MTC特异性突变分析(100% vs 25%;P = .03)。

核心结论

  • 基于ThyraMIR结果的配对miRNA表达分析能准确预测甲状腺FNA样本中的MTC,包括细胞学结果不确定的样本。

研究设计与样本

  • 发现队列为30例福尔马林固定石蜡包埋的良恶性甲状腺肿瘤(含4例MTC),进行配对差值分析。
  • 分析验证后,使用3个独立临床验证队列(共7557份标本)进行临床验证。
  • miRNA相对丰度来自ThyraMIR检测结果,基因改变采用ThyGeNEXT panel二代测序识别。

主要发现

  • 发现队列中,Kruskal-Wallis检验识别出9个配对差异具有显著区分MTC与非MTC样本的能力(P < .0001)。
  • 分析验证研究及3个临床验证队列中,检测均正确分类所有MTC与非MTC样本。
  • 总体检测准确率为100%(95%置信区间,99%-100%)。
  • 在细胞学不确定的FNA样本中,配对分析灵敏度为100%,MTC特异性突变分析为25%(P = .03)。

关键数值与推荐

  • 配对差值分析通过将一个miRNA的临界阈值从其他miRNA的临界阈值中减去来实现。
  • 发现队列中9个配对差异以Kruskal-Wallis检验P < .0001区分MTC与非MTC样本。
  • 总体检测准确率100%(95%CI 99%-100%)。
  • 细胞学不确定样本中配对分析灵敏度100% vs MTC特异性突变分析25%(P = .03)。

临床怎么用

  • 对于甲状腺FNA样本,尤其是细胞学结果不确定者,可考虑配对miRNA表达分析辅助识别MTC。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Medullary thyroid carcinoma (MTC) is an aggressive malignancy originating from the parafollicular C cells. Preoperatively, thyroid nodule fine-needle aspiration cytology (FNAC) and pathogenic gene mutations are definitive in approximately one-half of cases. MicroRNAs (miRNAs) are endogenous, noncoding, single-stranded RNAs that regulate gene expression, a characteristic that confers the potential for identifying malignancy. In the current study, the authors hypothesized that differential pairwise (diff-pair) analysis of miRNA expression levels would reliably identify MTC in FNA samples. METHODS: The relative abundance of 10 different miRNAs in total nucleic acids was obtained from ThyraMIR test results. Diff-pair analysis was performed by subtracting the critical threshold value of one miRNA from the critical threshold values of other miRNAs. Next-generation sequencing with the ThyGeNEXT panel identified oncogenic gene alterations. The discovery cohort consisted of 30 formalin-fixed, paraffin-embedded benign and malignant thyroid neoplasms, including 4 cases of MTC. After analytical validation, clinical validation was performed using 3 distinct cohorts (total of 7557 specimens). RESULTS: In the discovery cohort, 9 diff-pairs were identified as having significant power using the Kruskal-Wallis test (P < .0001) to distinguish MTC samples from non-MTC samples. The assay correctly classified all MTC and non-MTC samples in the analytical validation study and in the 3 clinical validation cohorts. The overall test accuracy was 100% (95% confidence interval, 99%-100%). In indeterminate FNAC samples, the sensitivity of the diff-pair analysis was greater than that of the MTC-specific mutation analysis (100% vs 25%; P = .03). CONCLUSIONS: Pairwise miRNA expression analysis of ThyraMIR results were found to accurately predict MTC in thyroid FNA samples, including those with indeterminate FNAC findings.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Ciarletto AM, Narick C, Malchoff CD, et al. Analytical and clinical validation of pairwise microRNA expression analysis to identify medullary thyroid cancer in thyroid fine-needle aspiration samples. Cancer Cytopathol. 2020. PMID: 33017868. doi:10.1002/cncy.22365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。